AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05904743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza
Description: Pharmaceutical form: powder Route of administration: inhalation
Study NCT05904743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT05904743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-acting Insulin Analog
Description: Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Study NCT05904743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin
Description: Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Study NCT05331768 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: banding ligation plus terlipressin infusion
Description: Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
Study NCT05331768 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: banding ligation plus terlipressin infusion
Description: Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
Study NCT05731882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-SeaLA, CardioPulse PFA system
Description: First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
Study NCT05351060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom Fabricated Splint
Description: Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
Study NCT06076473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Untargeted metabolomics
Description: Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
Study NCT06405516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous blood cell salvage with in-house device
Description: In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
Study NCT06405516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous cell salvage with i-Sep SAME device
Description: In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom made insole
Description: Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises of extrinsic foot muscles
Description: Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises of extrinsic foot muscles
Description: Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises of intrinsic foot muscles
Description: The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises of intrinsic foot muscles
Description: The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
Study NCT05056298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insole
Description: Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
Study NCT06348498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jia Shen Tablet
Description: Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
Study NCT05662293 — intervention group
Intervention type: OTHER
Intervention: Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)
Description: Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
Study NCT05662293 — intervention group
Intervention type: OTHER
Intervention: Data collection: Quality of Life (QoL) Questionnaire (prospective part)
Description: Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life.
Study NCT05662293 — intervention group
Intervention type: OTHER
Intervention: Data collection (retrospective study)
Description: Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
Study NCT05662293 — intervention group
Intervention type: OTHER
Intervention: Data collection (prospective study database)
Description: Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
Study NCT05265091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL590586 Capsule
Description: Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
Study NCT01228110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortison
Study NCT01228110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study NCT04875988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly iQ+ Ultrasound
Description: ultrasound will be used in the intervention group for IV access
Study NCT04875988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: ultrasound will not be used in the traditional IV placement group
Study NCT05615870 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Winix 5500-2 HEPA filtration units
Description: To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
Study NCT05615870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Winix 5500-2 HEPA filtration units
Description: To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
Study NCT05704335 — intervention group
Intervention type: OTHER
Intervention: Questionnaire administration
Description: A trained physician will administer a structured questionnaire
Study NCT04850859 — intervention group
Intervention type: OTHER
Intervention: measure various dimensions of the glenoid
Description: measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
Study NCT04850859 — intervention group
Intervention type: OTHER
Intervention: measure various dimensions of the acetabulum
Description: measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
Study NCT04700397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nitroglycerine
Description: We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
Study NCT06525636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration
Study NCT05751538 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03817034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
Study NCT06028581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding support system
Description: Using the breastfeeding support system
Study NCT06183203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
Study NCT06183203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
Study NCT04974814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg
Description: patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
Study NCT04974814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
Study NCT04974814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Test
Description: patients in control arm will not preloaded with statin in ER before PCI
Study NCT00899587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril
Description: enalapril 5 mg every night
Study NCT00899587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
Study NCT00899587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05253690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon catheter insertion approach for labor induction
Description: Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
Study NCT04908904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol
Description: Capsule with 12 mg cafestol
Study NCT04908904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule without cafestol
Study NCT04791540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: handgrip strenght
Description: Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MUST
Description: Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GLIM
Description: Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gut microbiota
Description: A fecal sample obtained at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood Sample
Description: A Blood sample obtained at admission (T0) and at decannulation time (T1)
Study NCT04791540 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measures
Description: Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
Study NCT05253690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon catheter insertion approach for labor induction
Description: Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
Study NCT04944810 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Gastric Bypass
Description: Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
Study NCT04944810 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Sleeve Gastrectomy
Description: Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
Study NCT04944810 — intervention group
Intervention type: PROCEDURE
Intervention: Revisional Bariatric Surgery
Description: Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
Study NCT04944810 — intervention group
Intervention type: PROCEDURE
Intervention: Nissen/Sleeve Gastrectomy with Magnetic Assistance
Description: Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
Study NCT04944810 — intervention group
Intervention type: PROCEDURE
Intervention: Mangetic General Surgery
Description: Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
Study NCT05489991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmPSMA-02
Description: Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
Study NCT04250233 — intervention group
Intervention type: DEVICE
Intervention: Respiratory Monitor
Description: All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
Study NCT04824391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC 3 µg/0.5 ml Vaccine
Description: Two IM applications on Days 1 and 28
Study NCT04824391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC 6 µg/0.5 ml Vaccine
Description: Two IM applications on Days 1 and 28
Study NCT04824391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two IM applications on Days 1 and 28
Study NCT06166537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Graduated compression stockings
Description: Graduated compression stockings are standard care (control)
Study NCT06166537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Graduated compression stockings
Description: No Graduated compression stockings is the intervention
Study NCT06424600 — intervention group
Intervention type: OTHER
Intervention: Gingival Index
Description: The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I > 2.00 confirmed severe gingival inflammation.
Study NCT06344533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003142 Injection
Description: JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Study NCT06344533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical Cream
Description: 5g 0.075% applied once
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10mg IV once
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 10mg IV once
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8mg IV once if needed
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 8mg IV once if needed
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers, Intravenous
Description: 1000cc once
Study NCT05098067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers, Intravenous
Description: 1000cc once
Study NCT06511323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
Description: at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
Study NCT05007041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD® Quadrivalent
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine